BML-111

BML-111

• CAS Number: 78606-80-1
• UNSPSC Description: BML-111, a lipoxin A4 analog, is a lipoxin A4 receptor agonist. BML-111 represses the activity of angiotensin converting enzyme (ACE) and increases the activity of angiotensinconverting enzyme 2 (ACE2). BML-111 has antiangiogenic, antitumor and anti-inflammatory properties[1][2].
• Target Antigen: Angiotensin-converting Enzyme (ACE)
• Type: Reference compound
• Related Pathways: Metabolic Enzyme/Protease
• Applications: COVID-19-anti-virus
• Field of Research: Cancer; Inflammation/Immunology; Cardiovascular Disease
• Assay Protocol: https://www.medchemexpress.com/bml-111.html
• Purity: 98.0
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O=C(OC)CCC[C@H](O)[C@H](O)CO
• Molecular Weight: 192.21
• References & Citations: [1]Ying Chen, et al. Lipoxin A4 and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: The Role of Antiangiogenesis. Mol Cancer Ther. 2010 Aug;9(8):2164-74.|[2]Qiong-Feng Chen, et al. BML-111, a Lipoxin Receptor Agonist, Protects Against Acute Injury via Regulating the Renin Angiotensin-Aldosterone System. Prostaglandins Other Lipid Mediat. 2019 Feb;140:9-17.|[3]T H Lee, et al. Inhibition of Leukotriene B4-induced Neutrophil Migration by Lipoxin A4: Structure-Function Relationships. Biochem Biophys Res Commun. 1991 Nov 14;180(3):1416-21.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: No Development Reported